Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going

摘要: The detection of measurable residual disease (MRD) has become a key investigation that plays role in the prognostication and management several hematologic malignancies. Acute myeloid leukemia (AML) is most common acute adults MRD AML still emerging. Prognostic markers are complex, largely based upon genetic cytogenetic aberrations. now being incorporated into prognostic models powerful predictor relapse. While PCR-based methods sensitive specific, many patients do not have an identifiable molecular marker. Immunophenotypic using multiparametric flow cytometry (MFC) widely applicable, on identification surface marker combinations present leukemic cells but normal hematopoietic cells. Current techniques include “different from normal” and/or “leukemia-associated immunophenotype” approach. Limitations MFC-based analyses lack standardization, reliance high-quality marrow aspirate, variable sensitivity. Emerging look to improve use dimensional reduction analysis, incorporating more specific identifying stem This review will discuss current together with new emerging determine MFC analysis.